copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
Published 5 years ago • 78 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
2:16
treating kidney cancer with axitinib &avelumab, or axitinib & pembrolizumab?
-
6:01
dart study: phase 2 study of dalantercept plus axitinib in advanced clear cell rcc
-
1:06
dr. pal on crispr-based technology in rcc
-
10:28
responses to traditional chemotherapy vs immunotherapy
-
1:57
dr. motzer on nivolumab versus everolimus in renal call carcinoma
-
1:27
probing the role of carbamylation in cell signaling and disease processes
-
1:26
development and implementation of a new kidney organoid model of nephrogenesis
-
2:53
molecular testing and tumor sidedness in crc
-
1:58
essential amino acids as diagnostic biomarkers of hepatocellular carcinoma | oncotarget
-
0:51
is there a similar rate of kidney failure with omicron compared to the delta variant?
-
15:26
comprehensive molecular characterization of chromophobe renal cell carcinoma - chad creighton
-
0:30
scott kopetz, md, phd, facp, explains how nivolumab is being incorporated into mcrc treatment
-
0:46
nih precision medicine initiative - by dr. judy crabtree
-
5:13
ifcc clinical case 16：hypoglycemic mystery
-
3:56
cuproptosis signature-related molecular subtype in gastric cancer
-
1:07
dr. ferraro on the use of molecular profiling in pancreatic cancer